Is Hyperbaric Oxygen Worth the Cost? What the Evidence Shows
Hyperbaric oxygen therapy (HBOT) — breathing 100 percent oxygen at elevated atmospheric pressure — is established medical treatment for decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, and radiation injury. Its recent promotion as a longevity intervention rests primarily on a single Israeli trial showing telomere lengthening and senescent cell reduction. This article provides an honest assessment of the established evidence and the longevity claims.
- Hyperbaric oxygen therapy (HBOT) involves breathing 100 percent oxygen at 1.5-3 atmospheres of pressure in a sealed chamber, producing systemic hyperoxia (blood and tissue oxygen partial pressures far exceeding what is achievable at normal atmospheric pressure). Established indications include: decompression sickness (the primary historical indication), carbon monoxide poisoning, air or gas embolism, necrotizing soft tissue infections, radiation injury, and diabetic foot ulcers with poor healing.
- The primary claimed longevity mechanisms of HBOT are: cyclical hyperoxia-normoxia cycles producing a hormetic stress response that activates HIF-1 alpha (hypoxia-inducible factor) on decompression; increased reactive oxygen species production that paradoxically activates antioxidant and protective gene expression; and direct effects on senescent cell biology and telomere maintenance.
- The Tel Aviv trial by Hachmo et al. (2020) gave 35 healthy adults aged 64 and older 60 HBOT sessions over 90 days. Telomere length in several types of immune cells rose by more than 20%, and senescent T helper cells fell by about 37%. It had no control group, so it is biologically interesting but not enough to recommend HBOT for longevity.
- The honest assessment: HBOT has proven value for its established medical uses. For healthy adults seeking longevity benefits, the evidence is one small uncontrolled trial measuring biomarkers, with no clinical outcomes. A longevity course runs to dozens of sessions, so the cost is substantial for that evidence.
- The safety profile of HBOT at therapeutic pressures (1.5-2.5 ATA) is generally favorable but not trivial: oxygen toxicity (seizures at very high pressures or prolonged exposures), middle ear barotrauma, sinus pain, temporary myopia, and in rare cases pulmonary oxygen toxicity are recognized adverse effects. Contraindications include untreated pneumothorax and certain medications.
Hyperbaric oxygen therapy began as a treatment for decompression sickness — the condition affecting divers who ascend too rapidly when nitrogen dissolved in blood and tissues comes out of solution as bubbles. Its subsequent use in carbon monoxide poisoning (where hyperbaric oxygen accelerates displacement of CO from hemoglobin) and radiation injury (where it promotes angiogenesis in hypoxic, radiation-damaged tissue) established it as legitimate medical therapy for specific, well-defined indications. The application of HBOT to general longevity promotion is considerably more recent and considerably less well-supported.1
The Physics and Physiology
At sea level breathing room air, oxygen partial pressure in arterial blood is approximately 95-100 mmHg, with hemoglobin approximately 97-98 percent saturated. Breathing 100 percent oxygen at 2-3 atmospheres absolute pressure produces arterial oxygen partial pressures of 1,500-2,000 mmHg — dissolving substantial additional oxygen in plasma (which can sustain life even without functioning hemoglobin). This systemic hyperoxia has several physiological effects: it promotes angiogenesis in hypoxic tissue (via HIF-1 alpha activation on pressure release), enhances neutrophil bactericidal activity (oxygen-dependent oxidative burst), promotes stem cell mobilization from bone marrow, and activates multiple antioxidant and stress-response gene expression programs via a hormetic ROS-activated mechanism.2
The Israeli Longevity Trial
The Hachmo et al. 2020 trial in Aging gave 35 healthy adults aged 64 and older 60 daily HBOT sessions at 2 ATA over 90 days. Telomere length in T helper, T cytotoxic, natural killer and B cells increased by more than 20%, most in B cells, and the number of senescent T helper cells fell by about 37%.3 Effects this large would be striking if confirmed.
The critical limitations that prevent recommending HBOT for healthy adults based on this trial: n=35 without a randomized control arm (no way to separate HBOT effects from time effects, regression to the mean, or placebo effects); surrogate biomarker endpoints (telomere length and senescent cell counts) without clinical outcome data; PCR-measured telomere length has substantial technical variability; and the trial has not been independently replicated. This is the kind of preliminary result that should generate larger, randomized, controlled trials — not immediate clinical recommendations.
Where HBOT Is Legitimate: The Established Indications
HBOT's evidence for its established uses is much stronger than its longevity evidence. For diabetic foot ulcers, a Cochrane review of 12 trials found that adding HBOT improved healing at six weeks, although the benefit was not evident at one year.4 It is also an accepted treatment for decompression sickness, carbon monoxide poisoning and some forms of radiation injury, and is used alongside surgery and antibiotics for severe soft tissue infections.5
The Cost-Evidence Calculus
A longevity course of 40 to 60 sessions costs thousands of dollars at private clinics, and the evidence behind it is one small uncontrolled trial measuring biomarkers. Compared with exercise, diet and sleep, which have far stronger evidence, the cost-benefit balance is unfavorable for most healthy adults. For people with established indications, HBOT provides genuine clinical value.
References
- 1Thom SR. "Hyperbaric oxygen: its mechanisms and efficacy." Plast Reconstr Surg. 2011;127 Suppl 1(Suppl 1):131S-141S. PubMed · DOI
- 2Bhutani S, Vishwanath G. "Hyperbaric oxygen and wound healing." Indian J Plast Surg. 2012;45(2):316-24. PubMed · DOI
- 3Hachmo Y, et al. "Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial." Aging (Albany NY). 2020;12(22):22445-22456. PubMed · DOI
- 4Kranke P, et al. "Hyperbaric oxygen therapy for chronic wounds." Cochrane Database Syst Rev. 2015;2015(6):CD004123. PubMed · DOI
- 5Undersea and Hyperbaric Medical Society. "Indications for hyperbaric oxygen therapy." UHMS. 2019.